CME - Indiadiabetesfoundation

CME FOR THE YEAR 2020

S.NO	DATE	SPEAKER	TOPIC
1.	18-01-2020	DR. A. RAMACHANDRAN	KEY TAKE WAYS FROM CAROLINA TRIAL: SU POINT OF VIEW
2.	20-01-2020	DR. A. RAMACHANDRAN	LATEST GUIDELINES ON DIABETES MANAGEMENT: WHAT DOES IT MEAN IN CLINICAL PRACTICE?
3.	25-01-2020	DR. A. RAMACHANDRAN	BASAL INSULIN INITIATION AND TITRATION – PATIENT CENTERED APPROACH IN INDIAN SETTINGS
4.	08-02-2020	DR. A. RAMACHANDRAN	EFFICACY OF DPP4i: THE TEST OF TIME
5.	11-02-2020	DR. A. RAMACHANDRAN	HYPOGLYCAEMIA AND GLYCAEMIC VARIABILITY THE LURKING SHARKS
6.	13-02-2020	PROF. LESZEK CZUPRYNIAK	MEAL TIME MASTERS: INTERNATIONAL PERSPECTIVE – TREAT to TARGET WITH INSULINS IN T2DM: WHAT, WHEN & WHY?
7.	14-02-2020	DR. A. RAMACHANDRAN	DIABETIC HEART DISEASE PERSONALIZED THERAPY
8.	20-02-2020	DR. ARUN RAGHAVAN	INSULIN INTENSIFICATION OPTION TO CONTROL POSTPRANDIAL

CME FOR THE YEAR 2019

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 16. 17. 18.

MS. MUMTAJ
MS. CHRISTINE

MS. MUTHUMARI
MS. PURNIMA

DR. LAVANYA

S.NO

DATE

SPEAKER

TOPIC

12-03-19

DR. NANDITHA ARUN

ACHIEVING GLYCEMIC CONTROL - EVOLVING NEW PRANDIAL INSULIN ANALOGUES

01-05-19

DR. A. RAMACHANDRAN

EMPRISE STUDY IMPLICATIONS TO PRACTICE

06-05-19

3M FIRM TO ALL NURSES

CLEANING DISINFECTION & STERILIZATION

07-05-19

DR. NANDITHA ARUN

ACHIEVING OPTIMAL GLYCEMIC CONTROL -EVOLVING ROLE OF PRANDIAL INSULINS

11-05-19

DR. NANDITHA ARUN

CLINICAL EXPERIENCE WITH GLA - 300- A CASE BASED DISCUSSION

11-05-19

MR. VIJAY - BIOCON PHARMA

BASICS OF DIABETES COMPLICATION & INSULIN TECHNIQUES

12-05-19

DR. A. RAMACHANDRAN

SEETTING THE CONTEXT - MODERATOR

23-05-19

DR. NANDITHA ARUN

LINKING THE DOTS WITH GLP – 1RAs: T2DM, CVD AND OTHER COMORBIDITIES

24-05-19

DR. A. RAMACHANDRAN

CARMELINA TRIAL – EVIDENCE ON CV AND HEART FAILURE SAFETY WITH LINAGLIPTIN

29-05-19

DR. ARUN RAGHAVAN

PRESENT DAY APPROACH TO CV MORTALITY REDUCTION IN T2DM

09-07-19

DR. A. RAMACHANDRAN

CILICAL APPROCH TO CARDIO – RENAL SYNDROME IN T2DM

09-08-19

DR. NANDITHA ARUN

MULTI – DISCIPLINARY MANAGEMENT OF OBESITY

16-08-19

DR. ARUN RAGHAVAN

GLP- 1 RA: STRIVING TOWARDS AHOLOSTIC MANAGEMENT OF T2DM

22-08-19

DIETICIAN PRESENTATION
class="column-4">– PROTEIN IN OUR DIALY DIET
DAILY DIET / INTERMITTENT FASTIN
SUGAR PRODUCTS, VEGAN DIET
15.

28-08-19

DR. ARUN RAGHAVAN

VERIFYING THE STATUS OF EARLY GLYCEMIC CONTROL IN T2DM

13-09-19

DR. NANDITHA ARUN

ACHIEVING OPTIMAL GLYCEMIC CONTROL- EVOLVING ROLE OF PRANDIAL INSULINS

18-11-19

DR. ARUN RAGHAVAN

SGLT2 - I AND YOU: NOVEL EMPAGLIFLOZIN REGIMENS FOR HOLISTIC CARDIOVASCULAR AND GLYCAEMIA CONTROL

11-12-19

DR. SANTHOSH JEYARAJ
-4">INITIATION OF PREMIXED INSULIN
OF SGLT2I IN T2DM & CLINICAL EVIDENCE OF REMOGLIFLOXIN

CME FOR THE YEAR 2018

S.NO	DATE	SPEAKER	TOPIC
1.	21-01-18	DR. A. RAMACHANDRAN	DAPAGLIFLOZIN- ROLE IN TREATMENT OPTIMIZATION
2.	28-01-18	DR. A. RAMACHANDRAN	LET US MEET BASAGLAR – A NEW TAKE ON INSULIN GLARGINE
3.	01-03-18	DR. PRAGNA	DIABETIC FOOT ULCER WITH CELLULITIS
4.	01-03-18	DR. GIRIDHAR	MATURITY ONSET OF DM OF THE YOUNG
5.	20-03-18	DR. ARUN RAGHAVAN	COMBINATION THERAPY: Right from the start?
6.	06-04-18	DR. ARUN RAGHAVAN	SIMPLIFYING INSULIN THERAPY FOR THE INDIAN PATIENT
7.	12-04-18	MR. ANAND	BASIC LIFE SUPPORT TRAINING CLASS BY CFILS TO ALL DOCTORS
8.	19-04-18	DR. KISHORE	DIABETIC NEPHROPATHY
9.	19-04-18	DR. LAVANYA	CPD - FIBRO CALCULOUS PANCREATIC DIABETES
10.	19-04-18	DR. ARUN RAGHAVAN	EMPOWERING CARDIO-METABOLIC OUTCOMES IN T2DM: LESSONS POST EMPA-REG OUT COME
11.	04-06-18	DR. NANDITHA ARUN	COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN: HERALDING AN ERA OF 360 MANAGEMENT OF T2D
12.	04-06-18	DR. ARUN RAGHAVAN	EMPOWERING CARDIOMETABOLIC OUTCOMES IN T2DM: LESSONS POST EMPA-REG OUTCOME’’
13.	09-06-18	DR. MOHAMMED ZAID	GLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF TYPE 2 DM
14.	09-06-18	DR. SANTHOSH JEYARAJ	ROLE OF PREMIX ANALOG IN THE MANAGEMENT OF DM
15.	10-06-18	DR. A. RAMACHANDRAN	CASE FROM CLINIC: A YOUNG OBESE FEMALE DIABETES PATIENTS
16.	20-06-18	MR. VIVEKANANDA	NEBULIZATION & INHALATION TECHNIQUES
17.	23-06-18	DR. A. RAMACHANDRAN	EMPAGLIFLOZIN/LINAGLIPTIN FDC: A LEAP TOWARDS HOLOSTIC T2D MANAGEMENT
18.	12-07-18	DR. VISHANTH	METOBOLIC SYNDROME
19.	12-07-18	DR. SHANMUGA PRIYA	DIABETES & PREGNANCY
20.	18-07-18	DR. ARUN RAGHAVAN	FROM LEAD TO LEADER – HbA1c TO HbA1CV
21.	21-07-18	DR. A. RAMACHANDRAN	DIABETES TODAY: PUTTING EVIDENCE INTO PRACTICE
22.	27-07-18	DR. NANDITHA ARUN	EVOLVING TREATMENT OPTIONS FOR PATIENTS WITH TYPE 2 DIABETES: STRIKING THE RIGHT BALANCE WITH NEWER INSULIN CO- FORMULATION
23.	28-07-18	DR. A. RAMACHANDRAN	DAWNING THE SPLENDOUR OF CARDIOPROTECTION IN DIABETES
24.	02-08-18	DR. K. V. ARUN	PERIODONTAL DISEASE & DIABETES – BIDIRECTIONAL RELATIONSHIP
25.	02-08-18	DR. P.D. MADAN KUMAR	ORAL CASE FOR DIABETES PATIENT – RECENT CONCEPTS
26.	04-08-18	DR. A. RAMACHANDRAN	COMPARING SECOND GENERATION BASAL INSULINS : A SPOTLIGHT ON THE BRIGHT STUDY
27.	10-08-18	DR. A. RAMACHANDRAN	INSULINS HAVE BECOME PATIENT FRIENDLY: MAKING TIMELY INSULIN INITIATION A REALITY
28.	17-08-18	DR. ARUN RAGHAVAN	I AM RISKING MY PATIENTS BY DELAYING INSULINIZATION
29.	26-09-18	DR. ARUN RAGHAVAN	WE LOOK FORWARD TO YOUR ESTEEMED PRESENCE AND PARTICIPATION!
30.	11-10-18	DR. NANDITHA ARUN	COMPARING SECOND GENERATION BASAL INSULINS : A SPOTLIGHT ON THE BRIGHT STUDY
31.	21-10-18	DR. A. RAMACHANDRAN	M. HEALTH: EMERGENCE OF NEW SCIENCE FOR DIABETES CARE AND PREVENTION
32.	26-10-18	DR. A. RAMACHANDRAN	CLINICAL IMPACT OF INITIATING INSULIN EARLY- ARE WE JUSTIFIED IN THE DELAY
33.	11-11-18	DR. ARUN RAGHAVAN	BASAL INSULIN CIRCLE
34.	15-11-18	DR. SANTHOSH JEYARAJ	LOGICAL CHOICE OF OAD: EMPHASIS ON GLIPTINS
35.	19-11-18	DR. A. RAMACHANDRAN	CV AND RENAL CO-MORBIDITIES WITH DIABETES: ELEPHANTS IN THE ROOM
36.	28-11-18	DR. NANDITHA ARUN	STENO – A TALE TO TELL
37.	09-12-18	DR. ARUN RAGHAVAN	INSULIN INITIATION IN T2DM PATIENTS INADEQUATELY CONTROLLED ON OADs
38.	14-12-18	DR. NANDITHA ARUN	PRESENT DAY APPROACH TO CV MORTALITY REDUCTION IN T2DM
39.	28-12-18	DR. NANDITHA ARUN	INSTRIDE 1 AND 2 SAFETY AND EFFICACY OF BIOCON INSULIN OTHER REFERENCE GLARGINE

CME FOR THE YEAR 2017

S.NO	DATE	SPEAKER	TOPIC
1.	02-03-17	MS. LANVANYA & MS. LAGNA	ROLE OF OILS & NUTS IN ONE’S DIET
2.	20-04-17	MS. GIFTA	FRUITS & VEGETABLES
3.	11-05-17	MS. SATHYA	NURSES & COMMUNICATION
4.	11-05-17	MS. ABIRAMY	NURSING SERVICE & HOLISTIC APPROACH
5.	11-05-17	MR. ANAND	A VOICE OF LEAD-NURSES DAY THEME 2017
6.	06-08-17	DR. NANDITHA ARUN	PREVENTION OF DIABETES - AN UPDATE
7.	20-08-17	DR. A. RAMACHANDRAN	DIABETES 360: EXPERTS VIEW ON MANAGING DIABETES COMPLICATIONS
8.	07-09-17	MS. NITHYASHRI	NUTRITIONAL SUPPORT IN YOUNG CHILDREN & TYPE 1 DM
9.	20-09-17	DR. ARUN RAGHAVAN	BASAL OPTIMIZATION WITH GLP-I ANALOGUE
10.	23-09-17	DR. A. RAMACHANDRAN	INDIAN PATIENT OF T2DM: WHAT DOES EVIDENCE MEAN TO CLINICAL PRACTICE?
11.	21-10-17	DR. HENRI FROM FINLAND	SLEEP DISORDER OF DIABETES
12.	21-10-17	DR. SANTHOSH JEYARAJ	ASK THE EXPERT-OVERWEIGHT OR MAJORITY-RIGHT PATIENT FOR SGLT2i
13.	16-11-17	DR. VAIBHAV	CASE PRESENTATION – TYPE 1 DM & HTN
14.	16-11-17	DR. BHAMA	CASE PRESENTATION – DIABETIC FOOT INFECTION
15.	22-12-17	DR. A. RAMACHANDRAN	CLINICAL IMPACT OF INITIATING INSULIN EARLY
16.	22-12-17	DR. ARUN RAGHAVAN	INITIATING INSULIN THERAPY: CLINICAL BENEFITS OF NEW INSULIN CO -FORMULATION
17.	23-12-17	DR. ARUN RAGHAVAN	EMERGING ROLE OF GLP1 ANALOQUSE IN T2DM: CARDIOVASCULAR AND RENAL OUTCOMES

CME FOR THE YEAR 2016

S.NO	DATE	SPEAKER	TOPIC
1.	25-01-16	DR. PETER LIN	METABOLIC STATE IN INDIAN TYPE 2 DIABETES
2.	28-07-16	DR. CHANDRASEKARAN	RENAL SPECIFIC NUTRITION
3.	20-02-16	DR. NANDITHA ARUN	CANAGLIFLOXIN: PLACE IN THERAPY FOR INDIAN DIABETICS
4.	23-02-16	DR. NANDITHA ARUN	IMPROVING METABOLIC STATE IN TYPE 2 DIABETES WITH SGLT2i
5.	28-02-16	DR. ARUN RAGHAVAN	IMPROVING METABOLIC STATE IN TYPE 2 DIABETES WITH SGLT2i
6.	03-12-16	DR. NANDITHA ARUN	OVERCOMING CHALLENGES IN HYPERGLYCEMIC MANAGEMENT
7.	22-04-16	DR. NANDITHA ARUN	TRULICITY LAUNCH
8.	05-07-16	DR. ARUN RAGHAVAN	ADVANCING DIABETES CARE WITH GLP-1 RECEPTOR AGONISTS
9.	01-12-16	Dr. A. RAMACHANDRAN	RESOLVING HBA1C PARADOX IN MANAGEMENT OF TYPE 2 DIABETES
10.	23-01-16	Dr. A. RAMACHANDRAN	CAN WE CHANGE THE HISTORY OF TYPE 2 DIABETES
11.	30-01-16	Dr. A. RAMACHANDRAN	SGLT2I – NEW PARADIGM IN DIABETES
12.	02-07-16	Dr. A. RAMACHANDRAN	ASIAN INDIANS - ARE WE DIFFERENT?
13.	03-03-16	Dr. A. RAMACHANDRAN	TRULICITY LAUNCH MEETING
14.	15-05-16	Dr. A. RAMACHANDRAN	CARDIOVASCULAR RISK MANAGEMENT IN DIABETES

CME FOR THE YEAR 2015

S.NO	DATE	SPEAKER	TOPIC
1.	02-12-15	DR. G. MANOHARAN, PLASTIC SURGEON	DIABETIC FOOT ULCER
2.	19-03-15	DR. NIVIEN	DIABETIC RETINOPATHY
3.	04-02-15	DR. RAM JAGANATHAN	ROUTINE PREDICTION OF TYPE 2 DIABETES
4.	04-02-15	DR. SELVAM	PREVENTION OF TYPE 2 DIABETES
5.	04-06-15	DR. UMA MAHESH	GLP ANALOGUES IN TYPE 2 DIABETES
6.	04-06-15	DR. SANTHOSH JAYARAJ	DPP4 INHIBITORS IN TYPE 2 DIABETES
7.	23-06-15	MARY CATHERIN	OVERVIEW OF PROJECTS IMPLEMENTATION
8.	13-08-15	DR. GIRISH	ROLE OF PLASTIC SURGEON IN DIABETES
9.	20-08-15	DR. T. M.BA LAKRISHNAN	MICROVASCULAR RECONSTRUCTION IN REVASCULARISED DIABETIC FOOT
10.	20-06-15	DR. NANDITHA ARUN	WHAT AFTER METFORMIN : CANAGLIPTOSIS
11.	21-06-15	DR. NANDITHA ARUN	ARE WESTERN GUIDELINES FOR DIABETES & DYSLIPIDEMIA HELPING OUR PATIENTS?
12.	26-06-15	DR. NANDITHA ARUN	EMERGING ROLE OF THE KIDNEY AS A TARGET OF THERAPY
13.	15-07-15	DR. NANDITHA ARUN	GLYCEMIC VARIABILITY
14.	20-06-15	DR. NANDITHA ARUN	WHAT AFTER METFORMIN : CANAGLIPTOSIS
15.	21-06-15	DR. NANDITHA ARUN	ARE WESTERN GUIDELINES FOR DIABETES & DYSLIPIDEMIA HELPING OUR PATIENTS?
16.	26-06-15	DR. NANDITHA ARUN	EMERGING ROLE OF THE KIDNEY AS A TARGET OF THERAPY
17.	15-07-15	DR. NANDITHA ARUN	GLYCEMIC VARIABILITY

CME FOR THE YEAR 2014

S.NO	DATE	SPEAKER	TOPIC
1.	20-03-14	Dr. V. B. NARAYANA MURTHY	SCOPE AND DEATH OF PLASTIC SURGERY IN PREVENTION OF DIABETIC FOOT ULCERS
2.	04-01-14	Dr. ARAVINDAN SELVARAJ	DIABETIC PERIARTHRITIS IS A SURGICAL DISEASE
3.	08-05-14	Dr. ARAVINDAN SELVARAJ	GLYCAEMIC CONTROL IN ICU'S
4.	31-07-14	Dr. LATHA DULIPRINGH	OSTEOPOROSIS, FRACTURES & BEYOND
5.	21-08-14	Dr. PRITHIKA CHARY	NEUROLOGICAL MANIFESTATIONS IN DIABETES
6.	25-09-14	Prof. M. MADHAVAN	CURRENT CONCEPTS ON THE USE OF ORAL HYPOGLYCEMIC AGENT
7.	18-04-14	Dr. S. SUBRAMANIAN	PNEUMOCOCCAL VACCINATION IN SPECIAL POPULATION
8.	16-10-14	Dr. PANEERSELVAM	INTERESTING CARE STUDIES IN DIABETES

India Diabetes Research Foundation (IDRF) is a pioneer research institution established by Prof. A. Ramachandran in 2007 and is involved in multifarious research activities in diabetes health care and in diabetes education, imparting knowledge to students and the general public. The research publications of the IDRF and its impacts have been acknowledged internationally and have put India in the world map of diabetes research especially in the field of epidemiology (population studies) and primary prevention of diabetes.